Zinbryta vs. Tysabri

Zinbryta (daclizumab) and Tysabri (natalizumab) are monoclonal antibodies used to treat adult patients with relapsing forms of multiple sclerosis (MS).

Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this condition.

Side effects of Zinbryta and Tysabri that are similar include runny or stuffy nose, skin rash (including drug rash), sore throat, and depression.

Side effects of Zinbryta that are different from Tysabri include upper respiratory tract infection, bronchitis, influenza, mouth pain, eczema, swollen lymph nodes, increased alanine aminotransferase (ALT), anemia, acne, and fever.

Side effects of Tysabri that are different from Zinbryta include headache, tired feeling, joint or muscle pain, redness or irritation at the injection site, swelling hands/feet/ankles, changes in menstrual cycle, painful menstrual cramps, stomach pain, diarrhea, and cold symptoms.

Zinbryta may interact with drugs or herbal products that are toxic to the liver.

Tysabri may interact with other medicines, especially those that may affect the immune system such as: interferon, cyclosporine, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, and chemotherapy or radiation treatments.

Common side effects of Zinbryta include:

• runny or stuffy nose
• upper respiratory tract infection
• rash, including drug rash
• influenza
• skin rash
• mouth pain
• sore throat
• bronchitis
• eczema
• swollen lymph nodes
• depression
• increased alanine aminotransferase (ALT)
• acne
• anemia, and
• fever

Less common side effects of Zinbryta include:

• abnormal liver function test,
• decreased lymphocyte count
• diarrhea
• dry skin
• skin redness
• hair bumps (folliculitis)
• increased liver enzymes
• laryngitis
• enlarged lymph nodes
• pneumonia
• itching
• psoriasis
• skin peeling
• toxic skin eruption, and
• viral infection

Common side effects of Tysabri include:

• headache,
• tired feeling,
• joint or muscle pain,
• redness or irritation at the injection site,
• swelling hands/feet/ankles,
• changes in menstrual cycle,
• stomach pain,
• diarrhea,
• skin rash,
• depression,
• painful menstrual cramps, or
• cold symptoms such as stuffy nose, sneezing, or sore throat.

Tell your doctor if you have side effects while Tysabri is being given or shortly after your treatment is finished (infusion reaction) including:

• chills,
• fever,
• flushing,
• nausea,
• dizziness, and
• chest pain.

Zinbryta (daclizumab) injection is an interleukin-2 receptor blocking antibody indicated for the treatment of adult patients with relapsing forms of multiple sclerosis (MS). Because of its safety profile, the use of Zinbryta should generally be reserved for patients who have had an inadequate response to two or more drugs indicated for the treatment of MS.

Tysabri (natalizumab) is a monoclonal antibody used in to treat relapsing forms of multiple sclerosis. Tysabri is also used to treat moderate to severe Crohn's disease in adults. Tysabri is usually given after other Crohn's disease medications have been tried without successful treatment of this condition.

Zinbryta may interact with hepatotoxic drugs or herbal products. Tell your doctor all medications and supplements you use. Tell your doctor if you are pregnant before taking Zinbryta. It is unknown if it would affect a fetus. It is unknown if Zinbryta passes into breast milk or if it would affect a nursing infant. Consult your doctor before breastfeeding.

Tysabri may interact with other medicines, especially those that may affect the immune system such as: interferon, cyclosporine, sirolimus, tacrolimus, basiliximab, efalizumab, muromonab-CD3, mycophenolate mofetil, azathioprine, leflunomide, etanercept, or chemotherapy or radiation treatments.

The recommended dosage of Zinbryta is 150 milligrams once monthly.

The recommended dose of Tysabri for multiple sclerosis or Crohn's disease is 300 mg intravenous infusion over one hour every four weeks.